Clinical Trial Update: Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Clinical trial update notes that a Phase 3 study of desvenlafaxine sustained-release (DVS-SR) for adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Desvenlafaxine Sustained-Release (DVS-SR) (desvenlafaxine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED